Current Modalities and Mechanisms Underlying Cardioprotection by Ischemic Conditioning

John H. Rosenberg, John H. Werner, Michael J. Moulton, Devendra K. Agrawal

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Ischemic preconditioning is a process which serves to mitigate reperfusion injury. Preconditioning of the heart can be achieved through natural, pharmacological, and mechanical means. Mechanical preconditioning appears to have the greatest chance of good outcomes while methods employing pharmacologic preconditioning have been largely unsuccessful. Remote ischemic preconditioning achieves a cardioprotective effect by applying cycles of ischemia and reperfusion in a distal limb, stimulating the release of a neurohumoral cardioprotective factor incited by stimulation of afferent neurons. The cardioprotective factor stimulates the reperfusion injury salvage kinase (RISK) and survivor activator factor enhancement (SAFE) signaling cascades in cardiomyocytes which promote cell survival by the expression of anti-apoptotic genes and inhibition of the opening of mitochondrial permeability transition pores. Clinical application of ischemic preconditioning involving targets in the RISK and SAFE signaling appears promising in the treatment of acute myocardial infarction; however, clinical trials have yet to demonstrate additional benefit to current therapy.

Original languageEnglish (US)
Pages (from-to)1-16
Number of pages16
JournalJournal of Cardiovascular Translational Research
DOIs
StateAccepted/In press - May 24 2018

Fingerprint

Ischemic Preconditioning
Reperfusion Injury
Phosphotransferases
Afferent Neurons
Cardiac Myocytes
Reperfusion
Cell Survival
Ischemia
Extremities
Myocardial Infarction
Clinical Trials
Pharmacology
Therapeutics
Genes

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Pharmaceutical Science
  • Cardiology and Cardiovascular Medicine
  • Genetics(clinical)

Cite this

Current Modalities and Mechanisms Underlying Cardioprotection by Ischemic Conditioning. / Rosenberg, John H.; Werner, John H.; Moulton, Michael J.; Agrawal, Devendra K.

In: Journal of Cardiovascular Translational Research, 24.05.2018, p. 1-16.

Research output: Contribution to journalArticle

@article{abcbbefbcf264d95ac76efb1c9e902a6,
title = "Current Modalities and Mechanisms Underlying Cardioprotection by Ischemic Conditioning",
abstract = "Ischemic preconditioning is a process which serves to mitigate reperfusion injury. Preconditioning of the heart can be achieved through natural, pharmacological, and mechanical means. Mechanical preconditioning appears to have the greatest chance of good outcomes while methods employing pharmacologic preconditioning have been largely unsuccessful. Remote ischemic preconditioning achieves a cardioprotective effect by applying cycles of ischemia and reperfusion in a distal limb, stimulating the release of a neurohumoral cardioprotective factor incited by stimulation of afferent neurons. The cardioprotective factor stimulates the reperfusion injury salvage kinase (RISK) and survivor activator factor enhancement (SAFE) signaling cascades in cardiomyocytes which promote cell survival by the expression of anti-apoptotic genes and inhibition of the opening of mitochondrial permeability transition pores. Clinical application of ischemic preconditioning involving targets in the RISK and SAFE signaling appears promising in the treatment of acute myocardial infarction; however, clinical trials have yet to demonstrate additional benefit to current therapy.",
author = "Rosenberg, {John H.} and Werner, {John H.} and Moulton, {Michael J.} and Agrawal, {Devendra K.}",
year = "2018",
month = "5",
day = "24",
doi = "10.1007/s12265-018-9813-1",
language = "English (US)",
pages = "1--16",
journal = "Journal of Cardiovascular Translational Research",
issn = "1937-5387",
publisher = "Springer New York",

}

TY - JOUR

T1 - Current Modalities and Mechanisms Underlying Cardioprotection by Ischemic Conditioning

AU - Rosenberg, John H.

AU - Werner, John H.

AU - Moulton, Michael J.

AU - Agrawal, Devendra K.

PY - 2018/5/24

Y1 - 2018/5/24

N2 - Ischemic preconditioning is a process which serves to mitigate reperfusion injury. Preconditioning of the heart can be achieved through natural, pharmacological, and mechanical means. Mechanical preconditioning appears to have the greatest chance of good outcomes while methods employing pharmacologic preconditioning have been largely unsuccessful. Remote ischemic preconditioning achieves a cardioprotective effect by applying cycles of ischemia and reperfusion in a distal limb, stimulating the release of a neurohumoral cardioprotective factor incited by stimulation of afferent neurons. The cardioprotective factor stimulates the reperfusion injury salvage kinase (RISK) and survivor activator factor enhancement (SAFE) signaling cascades in cardiomyocytes which promote cell survival by the expression of anti-apoptotic genes and inhibition of the opening of mitochondrial permeability transition pores. Clinical application of ischemic preconditioning involving targets in the RISK and SAFE signaling appears promising in the treatment of acute myocardial infarction; however, clinical trials have yet to demonstrate additional benefit to current therapy.

AB - Ischemic preconditioning is a process which serves to mitigate reperfusion injury. Preconditioning of the heart can be achieved through natural, pharmacological, and mechanical means. Mechanical preconditioning appears to have the greatest chance of good outcomes while methods employing pharmacologic preconditioning have been largely unsuccessful. Remote ischemic preconditioning achieves a cardioprotective effect by applying cycles of ischemia and reperfusion in a distal limb, stimulating the release of a neurohumoral cardioprotective factor incited by stimulation of afferent neurons. The cardioprotective factor stimulates the reperfusion injury salvage kinase (RISK) and survivor activator factor enhancement (SAFE) signaling cascades in cardiomyocytes which promote cell survival by the expression of anti-apoptotic genes and inhibition of the opening of mitochondrial permeability transition pores. Clinical application of ischemic preconditioning involving targets in the RISK and SAFE signaling appears promising in the treatment of acute myocardial infarction; however, clinical trials have yet to demonstrate additional benefit to current therapy.

UR - http://www.scopus.com/inward/record.url?scp=85047310769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047310769&partnerID=8YFLogxK

U2 - 10.1007/s12265-018-9813-1

DO - 10.1007/s12265-018-9813-1

M3 - Article

SP - 1

EP - 16

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

SN - 1937-5387

ER -